NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (Zelrix). PATH shares plunged to $2.06 at pre-market trading hours. PATH traded over 5.7M shares compared to 204K 10day average volume. Our […]